Table 3.
Univariate analysis of immunohistochemical findings and their association with axillary lymph node metastasis
| Factor | Unadjusted odd ratio and 95% confidence interval |
ALNM negative (n = 94) |
ALNM positive (n = 116) |
P value |
|---|---|---|---|---|
| ER | 1.14 (0.62-2.07) | 63/92 (68.5%) | 79/111 (71.2%) | 0.677 |
| PR | 1.13 (0.62-2.07) | 64/92 (69.6%) | 80/111 (72.1%) | 0.695 |
| HER2 | 1.28 (0.64-2.56) | 17/92 (18.5%) | 25/111 (22.5%) | 0.479 |
| CK5 | 0.25 (0.10-0.61) | 21/86 (24.4%) | 7/95 (7.4%) | 0.002 |
| CK14 | 0.28 (0.09-0.91) | 12/73 (16.4%) | 4/77 (5.2%) | 0.034 |
| CK17 | 0.38 (0.09-1.52) | 7/72 (9.7%) | 3/77 (3.9%) | 0.198 |
| P53 | 0.95 (0.48-1.88) | 23/71 (32.4%) | 25/80 (31.3%) | 0.880 |
| Ki67 | 1.51 (0.80-2.82) | 33/78 (42.3) | 42/80 (52.5%) | 0.200 |
| EGFR | 0.35 (0.15-0.82) | 20/61 (32.8%) | 10/69 (14.5%) | 0.013 |
| ER/PR/HER2 profile | ||||
| ER/PR+, HER2- | Reference | 59/92 (64.1%) | 71/111 (64.0%) | |
| ER/PR+, HER2+ | 1.50 (0.48-4.70) | 5/92 (5.4%) | 9/111 (8.1%) | 0.488 |
| ER/PR-, HER2+ | 1.11 (0.49-2.53) | 12/92 (13.0%) | 16/111 (14.4%) | 0.806 |
| ER/PR-, HER2- | 0.78 (0.36-1.71) | 16/92 (17.4%) | 15/111 (13.5%) | 0.532 |
| Triple-negative tumor | 0.74 (0.35-1.60) | 16/92 (17.4%) | 15/111 (13.5%) | 0.445 |
| Basal-like tumor | 0.25 (0.08-0.80) | 12/92 (13.0%) | 4/111 (3.6%) | 0.017 |
Unless otherwise stated, data are expressed as n (%).ALNM, axillary lymph node metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CK, cytokeratin